Weight Loss & Metabolic / side effects and safety / Last reviewed 2026-06-01

Tirzepatide Side Effects: Safety Signals and Warnings

Tirzepatide safety concerns are compound-specific. The main listed side effects are Nausea, Diarrhea, and Decreased appetite. The main warning signals are Boxed warning: thyroid C-cell tumors in rodents, Contraindicated with MTC history, and Pancreatitis risk.

Read the full Tirzepatide guide Browse answer pages

Direct Answer

Tirzepatide is now the default evidence-backed winner for weight loss among approved incretin drugs: SURMOUNT-5 showed greater weight reduction than semaglutide, and Zepbound also has an FDA indication for moderate-to-severe OSA in adults with obesity. Semaglutide still leads on mature cardiovascular outcomes evidence, but tirzepatide leads on weight-loss magnitude.

Evidence grade
Level A
Research status
FDA Approved
Category
Weight Loss & Metabolic
Best for
Obesity, type 2 diabetes, obstructive sleep apnea with obesity, metabolic syndrome research

Reported Side Effects

Warnings

Known or Plausible Interactions

Regulatory Context

FDA-approved for type 2 diabetes (Mounjaro, 2022), chronic weight management (Zepbound, 2023), and moderate-to-severe obstructive sleep apnea in adults with obesity (Zepbound, December 20, 2024). Prescription required. Availability may be limited due to high demand.

Evidence Snapshot

Evidence gradeLevel A
Research statusFDA Approved
Best supported outcomesWeight Loss (Level A), Blood Sugar Control (Level A), Obstructive Sleep Apnea (Level A), and GI Side Effects (Level A)
Primary citation count4
Last reviewed2026-06-01

Related Guides

How to Cite This Page

ExaminePeptides. "Tirzepatide Side Effects: Safety Signals and Warnings." Last reviewed 2026-06-01. https://examinepeptides.com/answers/tirzepatide-side-effects-safety/

This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.